Premium
Evaluation of Doxycycline Administration in Patients with Renal Failure and in Normal Subjects
Author(s) -
CURTIS J. R.,
KOUTSAIMANIS K. G.,
BUGGEY D.,
EASTWOOD J. B.
Publication year - 1973
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1973.tb12188.x
Subject(s) - doxycycline , medicine , nephrotoxicity , creatinine , renal function , chronic renal failure , uremia , hemodialysis , antibiotics , urology , gastroenterology , kidney , surgery , chemistry , biochemistry
Summary The biological half‐life of doxycycline in serum was determined in 6 normal subjects and in 8 patients on maintenance haemodialysis. There was no significant difference in the half‐life in the 2 groups. In 6 patients on maintenance haemodialysis the half‐life of doxycycline was determined both during and between haemodialysis. There was a tendency for the half‐life to be shorter during haemodialysis, but the differences were not statistically significant. It is concluded that no adjustment of dosage is required when doxycycline is employed in patients with severe renal failure, whether they are undergoing haemodialysis or not. Renal function was studied in 2 normal subjects who were given doxycycline in normal doses for 1 month. During this period there was no change in blood urea concentration, endogenous creatinine clearance or renal concentrating ability. Doxycycline was administered in normal doses to 8 patients with varying degrees of chronic renal failure for periods varying from 10 to 15 days. There was no evidence that doxycycline had any anti‐anabolic effect and there was no evidence of nephrotoxicity. No toxic effects were noted in any of the patients studied. Doxycycline is therefore of particular value when a broad spectrum antibiotic is required in patients with renal failure.